top of page

Occam Places Emanuele Ostuni as CEO of ARTBIO

ARTBIO, currently in stealth mode, is developing radioligand therapies for the treatment of cancers—with prostate, solid tumors, osteosarcoma, pancreatic, and non-small cell lung cancer being its initial focus.

In early 2022, Occam recruited Emanuele Otsuni, PhD as the company’s first CEO. Prior to assuming the CEO role at ARTBIO, Emanuele served as Head of European Cell & Gene Therapy programs at Novartis.

bottom of page